Breckenridge signs new product agreement with PTS Pharma


BERLIN, Conn., April 22, 2022 /PRNewswire/ — Breckenridge Pharmaceutical, Inc. today announced that it has signed a new product agreement with PTS Pharma, LLC. under which PTS will support a technology transfer to Towa Pharmaceutical Europe, SL of a complex product “For Suspension” developed by PTS. The rest of the development and commercialization will be carried out at the Towa plant. According to industry sales data, the product and its generics have recorded annual sales of approximately $75 million in the twelve months ending February 2022. The companies are actively negotiating and are eager to collaborate on additional complex formulations under the same business model.

About Breckenridge:
Breckenridge Pharmaceutical, Inc., a subsidiary of Towa Pharmaceutical (Osaka, Japan), partners with manufacturers nationwide and around the world to bring quality, cost-effective generic pharmaceutical products to American patients. Through our dedication to customer service, on-time delivery, reliable supply and quality manufacturing, we improve the health and quality of life of the patients we and our customers serve.

About PTS Pharma, LLC:
PTS Consulting, LLC and PTS Pharma LLC., is a Kansas-based formulation development, clinical trial production, regulatory services and analytical monitoring laboratory. PTS Consulting is actively involved in regulatory consulting services. PTS Pharma operations include the capability and expertise to develop complex formulations of tablets, capsules, granules, modified dosage forms, topical dosage forms, suppositories, film products, solution and suspension formulations, and sterile injectables. , with involvement in multiple DNA and DNA repositories over the years. Activities are hosted in dedicated GMP suites in the facility Kansas City, UNITED STATES. PTS Pharma is also involved in the clinical production of active raw materials through technological fermentation processes. The company was founded in 2003 by Paul Sudhakaran industry veteran who is the owner, president and CEO of the company.

For more information, please contact:
Breckenridge Pharmaceutical, Inc.
Robert GasparinoAssociate Vice President – ​​Business Development
Tel: 860-828-8140
E-mail: [email protected]

*All brand names and trademarks are the property of their respective owners.

SOURCE Breckenridge Pharmaceutical, Inc.


Comments are closed.